Restore Mind Medicine
"Rubberstamped"
Executive Compensation
Many of MindMed's "Completed" Corporate Goals were simply not met
"Execute R&D program and regulatory filings to
position for initiation of phase 2 study of MM-110"
"Advance clinical development programs of
MM-120 in GAD and ADHD to position for Phase 2
data readouts in 2023"
"A+"
MindMed's R&D program in MM-110 failed because MindMed failed to do
required regulatory studies.
MindMed was not positioned for the initiation of a Phase II study.
At the start of 2022, MindMed stated that the trial would begin "early 2022."
The trial started August 2022.
This delay of six-eight months resulted in MindMed not being positioned for
a Phase II readout in 2023.
MindMed has not provided any data to assess the MM-120 ADHD program.
Source: Company SEC Filings, Clinical trials.gov, MindMed Press Releases, MindMed Investor Presentations. See [3]
58View entire presentation